培美曲塞联合卡铂治疗晚期非小细胞肺癌的临床观察(2)
 |
| 第1页 |
参见附件(1928KB，3页)。
参考文献
[1]孙 燕，周际昌.临床肿瘤内科手册[M].北京：人民卫生出版社，2003：563-566.
[2]李树婷，马 飞，孙 燕.抗肿瘤代谢新药-培美曲塞.癌症进展杂志，2005，3(5)：471-476.
[3]何声秀，于爱珍，包兴才.多靶向抗叶酸药ALIMTA[J].国外医学：肿瘤分册，2003，30 (4)： 296-298.
[4]Calver H.MAT,a novel multitargeted antifolate,from preclinical to phase I and beyond :summary and conclusions[J].Semin Oncol,1999,26(2):1052-1108.
[5]孙 燕，王子平.抗肿瘤药物手册[M].北京大学医学出版社，2007：90-93.
[6]Gronberg BH，Bremnes RM，Flotten O.Phase III study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabin plus carboplatin as firstline chemotherapy in advanced nonsmallcell lung cancer[J].J Clin Oncol,2009,27(19):3217-3224.
[7]Scaglioti G,Parikh P,yon Pawel J,et al.Phase IIIstudy comparing cisplatin plus gemcitatine with cisplatin plus pemetrexed in chemotherapy:na?ve patients advancedstage nonsmall cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[8]Giovannetti E,Mey V,Nannizzi S,et al.Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human nonsmall cell lung cancer cells[J].Mol Pharmacol，2005，68(1):110-118.
[9]Huang C,Liu D,Nakano J，et al.E2F1 overexpression associated with TS and surving gene expressions in nonsmall cell lung cancer[J].J Clin Oncol,2007,25(Suppl):426s.
[10]Sowers R,Toguchida T,Qin J,et al.mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier,and thymidylate synthase mRNA expression in osteosarcoma[J].Mol Cancer Ther,2003,2(6):535-541.
[11]Salon C,Merdzhanova G,Brambilla C,et al.E2F1,Skp2 and cyclin E oncoproteins are pregulated and directly correlated in highgrade neuroendocrine lung tumors[J].Oneogene，2007,26(48):6927-6936.
(收稿日期：2010-09-14 修回日期：2010-10-31)
(编辑：崔群飞)
注：本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文
您现在查看是摘要介绍页，详见PDF附件(1928KB，3页)。